Follow the UNITED THERAPEUTICS CORPORATION share price and the full insider trade history of the company, a publicly traded company based in United States. Shares trade on the US market, under the oversight of SEC (Form 4). Market capitalisation: €21.9bn. The latest transaction was reported on 3 September 2026 (Notice of proposed sale (Form 144)). Among the most active insiders: PAUL MAHON. The full history is free.
10
Insider Decl.
n/a
Thresholds
n/a
n/a
Buy Volume
n/a
n/a
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate UNITED THERAPEUTICS CORPORATION Buy (bullish), based on 12 analysts. Average price target: US$664.33.
31Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 2,249 of 29,063 companies
76.1
score / 100
Value
61
Quality
91
FCF yld4.7%
Earn yld6.1%
EV/EBITDA12.2x
ROE19%
Gross mgn88%
Net mgn42%
Debt/EBITDA0.2x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
8,300 shares@ US$547.06540.019% mcap33.0% of flowCommonSEC144:0001950047-26-005618
10 of 10 declarations
About UNITED THERAPEUTICS CORPORATION
UNITED THERAPEUTICS CORPORATION is a biopharmaceutical company focused on developing treatments for rare diseases, particularly pulmonary arterial hypertension. It emphasizes innovation and improving patient care.